Cell Therapy as Treatment for Cerebral Palsy

Autologous Bone Marrow Mononuclear Cell Therapy in Cerebral Palsy

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02241395

Enrollment

Registered

2014-09-16

Start date

2013-08-31

Completion date

2018-12-31

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy

Keywords

Cerebral Palsy, autologous bone marrow mononuclear cells, stem cell

Brief summary

The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.

Interventions

BIOLOGICALIntrathecal autologous bone marrow mononuclear cell transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Months to 35 Years

Healthy volunteers

Inclusion criteria

* diagnosed cases of any type of Cerebral Palsy * age above 6 months.

Exclusion criteria

* presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/ Hepatitis C Virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[Hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia.

Design outcomes

Primary

Measure	Time frame	Description
change in clinical symptoms over a period of 2 years	2 years	Clinical symptoms such as oromotor skills, sitting and standing balance, speech, ambulation, muscle tone, cognition, hand and leg movement, walking, etc

Secondary

Measure	Time frame
Change in GMFM score	1 year
Change in Gross Motor Function Measure	1 year

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026